UniFirst Slips on Q3 Figures
UniFirst Corporation (NYSE: UNF) today reported results for its third quarter ended May 31, 2025 as compared to the corresponding period in the prior fiscal year:Consolidated revenues for the third quarter increased 1.2% to $610.8 million. Operating income was $48.2 million, a decrease of 0.6%.Net income increased to $39.7 million from $38.1 million in the prior year, or 4.3%. Diluted earnings per share increased to $2.13 from $2.03 in the prior year, or 4.9%.Adjusted EBITDA increased to $85.8 million compared to $84.8 million in the prior year, or 1.2%.The Company's financial results for the third quarter of fiscal 2025 and 2024 included approximately $1.0 million and $3.9 million, respectively, of costs directly attributable to its customer relationship management computer system and enterprise resource planning projects. The Company refers to the CRM and ERP projects together as its “Key Initiatives”. The effect of these items on the third quarter of fiscal 2025 and 2024 combined to decrease.CEO Steven Sintros said, “The results for our third quarter were largely in line with our expectations. It is rewarding to see our recent investments beginning to yield measurable returns, evidenced by gross margin improvement and more effective execution across the business.” UNF shares dipped $5.21, or 2.7%, to $185.20.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


